<code id='4FA5E63A23'></code><style id='4FA5E63A23'></style>
    • <acronym id='4FA5E63A23'></acronym>
      <center id='4FA5E63A23'><center id='4FA5E63A23'><tfoot id='4FA5E63A23'></tfoot></center><abbr id='4FA5E63A23'><dir id='4FA5E63A23'><tfoot id='4FA5E63A23'></tfoot><noframes id='4FA5E63A23'>

    • <optgroup id='4FA5E63A23'><strike id='4FA5E63A23'><sup id='4FA5E63A23'></sup></strike><code id='4FA5E63A23'></code></optgroup>
        1. <b id='4FA5E63A23'><label id='4FA5E63A23'><select id='4FA5E63A23'><dt id='4FA5E63A23'><span id='4FA5E63A23'></span></dt></select></label></b><u id='4FA5E63A23'></u>
          <i id='4FA5E63A23'><strike id='4FA5E63A23'><tt id='4FA5E63A23'><pre id='4FA5E63A23'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:93
          Adobe

          LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday. 

          The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired. 

          advertisement

          Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies. 

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Guidelines to prevent youth baseball injuries need more muscle
          Guidelines to prevent youth baseball injuries need more muscle

          Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

          read more
          Louisiana bill approved classifying abortion pills as controlled substances
          Louisiana bill approved classifying abortion pills as controlled substances

          AllenG.Breed/APBATONROUGE—Twoabortion-inducingdrugscouldsoonbereclassifiedascontrolledanddangeroussu

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Stroke rates rising, especially in working

          AdobeStrokeprevalencehasbeenclimbingoverthepastdecade,reversingasteadydeclineamongallAmericanswhiler